In fact, many studies have demonstrated potential strategies to enhance CXCL9/10 expression to enhance anti-tumor immunity: intratumoral delivery of a TLR2 agonist (FSL-1) with IFN-γ was shown to enhance CXCL10 expression and T cell infiltration in a TNBC mouse model51, and LNP-delivered IFN-α2 suppressed lung metastases through upregulation of Cxcl952. This evidence concerns the gene TLR2 and neoplasm.